Ramipril Concept

subject area of

• A population‐based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors  Academic Article
• Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials  Academic Article
• Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials  Academic Article
• Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes  Academic Article
• Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures  Academic Article
• Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)  Academic Article
• Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis  Academic Article
• Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries  Academic Article
• Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)  Academic Article
• Blood pressure and cardiovascular risk in the HOPE study  Academic Article
• Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies  Academic Article
• Blood-pressure reduction and cardiovascular risk in HOPE study  Academic Article
• Cardiovascular Risk in Patients with Early Renal Insufficiency  Academic Article
• Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk  Academic Article
• Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk  Academic Article
• Clinical decision making and the expected value of information  Academic Article
• Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study  Academic Article
• Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures  Academic Article
• Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study  Academic Article
• Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases  Academic Article
• Coronary artery disease - Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study  Academic Article
• Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study  Academic Article
• Development of Renal Disease in People at High Cardiovascular Risk  Academic Article
• Diabetes and the HOPE study: implications for macrovascular and microvascular disease.  Academic Article
• Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus  Academic Article
• Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies  Academic Article
• Dysglycemia and a History of Reproductive Risk Factors  Academic Article
• Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Academic Article
• Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction  Academic Article
• Effect of Ramipril on Cardiovascular Events in High-Risk Patients  Academic Article
• Effect of Ramipril on the Incidence of Diabetes  Academic Article
• Effect of Ramipril on the Incidence of Diabetes  Academic Article
• Effect of Rosiglitazone and Ramipril on β-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Academic Article
• Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results  Academic Article
• Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients  Academic Article
• Effect of long-term therapy with ramipril in high-risk women  Academic Article
• Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial  Academic Article
• Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose  Academic Article
• Effects of Ramipril and Vitamin E on Atherosclerosis  Academic Article
• Effects of Ramipril on Coronary Events in High-Risk Persons  Academic Article
• Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease  Academic Article
• Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial  Academic Article
• Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients  Academic Article
• Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial  Academic Article
• Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease  Academic Article
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy  Academic Article
• Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction  Academic Article
• Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both  Academic Article
• From the hope to the ontarget and the transcend studies: challenges in improving prognosis  Academic Article
• Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema  Academic Article
• Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk  Academic Article
• Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme  Academic Article
• Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction  Academic Article
• Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk  Academic Article
• Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial  Academic Article
• Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease  Academic Article
• Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study  Academic Article
• In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events  Academic Article
• Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal  Academic Article
• Is therapy of people with chronic kidney disease ONTARGET?  Academic Article
• Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])  Academic Article
• Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes  Academic Article
• Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes  Academic Article
• Modifying the natural history of atherosclerosis: the SECURE trial.  Academic Article
• More than just hype.  Academic Article
• Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice  Academic Article
• Preventing stroke with ramipril---authors' reply  Academic Article
• Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study  Academic Article
• Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study  Academic Article
• Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study  Academic Article
• Ramipril and Risk of Diabetes—Reply  Academic Article
• Ramipril and the Development of Diabetes  Academic Article
• Ramipril in the treatment of vascular diseases  Academic Article
• Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study  Academic Article
• Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.  Academic Article
• Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial  Academic Article
• Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials  Academic Article
• Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril  Academic Article
• Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE  Academic Article
• Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients  Academic Article
• Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial  Academic Article
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial  Academic Article
• Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies  Academic Article
• Role of Renin-Angiotensin System Blockade in Patients With Diabetes Mellitus  Academic Article
• Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes  Academic Article
• Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study  Academic Article
• Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)  Academic Article
• Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant Ul-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc.  Academic Article
• Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk  Academic Article
• Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease  Academic Article
• Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events  Academic Article
• Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.  Academic Article
• The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences  Academic Article
• The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.  Academic Article
• The HOPE study and diabetes  Academic Article
• The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct  Academic Article
• The Mini-Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk  Academic Article
• The Prognostic Significance of Bundle Branch Block in High-Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial  Academic Article
• The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics  Academic Article
• The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study  Academic Article
• The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial  Academic Article
• The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study  Academic Article
• The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis  Academic Article
• Use of ramipril in preventing stroke: double blind randomised trial  Academic Article
• Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study  Academic Article